Substrate-Dependent Ligand Inhibition of the Human Organic Cation Transporter OCT2

Mathew Belzer, Mark Morales, Bhumasamudram Jagadish, Eugene A. Mash, and Stephen H. Wright

Departments of Physiology (M.B., M.M., S.H.W.) and Chemistry (B.J., E.A.M.), University of Arizona, Tucson, Arizona

Received January 14, 2013; accepted May 23, 2013

ABSTRACT

Organic cation transporter 2 (OCT2) mediates the initial step in renal secretion of organic cations: uptake from the blood, across the basolateral membrane, and into the renal proximal tubule cells. Because of its potential as a target for unwanted drug-drug interactions (DDIs), considerable attention has been directed toward understanding the basis of OCT2 selectivity. These studies typically assess selectivity based on ligand inhibition profiles for OCT2-mediated transport of a probe substrate. However, little attention has been given to the potential influence of the substrate on the profile of ligand inhibition. Here we compared the IC50 values obtained for a set of structurally distinct inhibitors against OCT2-mediated transport of three structurally distinct substrates: 1-methyl-4-phenylpyridinium (MPP); metformin; and a novel fluorescent substrate, N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]ethanaminium iodide (NBD-MTMA). The median IC50 value for inhibition of MPP transport was 9-fold higher than that for inhibition of metformin transport. Similarly, the median IC50 value for inhibition of MPP transport was 5-fold higher than that for NBD-MTMA transport. However, this was not a systematic difference in inhibitory efficacy; the ratio of IC50 values, MPP versus NBD-MTMA, ranged from 88-fold (ipratropium) to 0.3-fold (metformin). These data show that 1) the choice of OCT2 substrate significantly influences both quantitative and qualitative inhibitory interactions with cationic drugs; and 2) ligand interactions with OCT2 are not restricted to competition for a common ligand binding site, consistent with a binding surface characterized by multiple, possibly overlapping interaction sites. Development of predictive models of DDIs with OCT2 must take into account the substrate dependence of ligand interaction with this protein.

Introduction

At physiologic pH, approximately 40% of all prescribed drugs are cationic (Neuhoff et al., 2003; Ahlin et al., 2008), and these organic cations (OCs) are potential substrates for one or more of the transport processes that mediate renal secretion of endogenous and exogenous OCs. The latter group includes many commonly prescribed drugs; consequently, OC transport influences their pharmacokinetic and pharmacodynamic profiles. The existence within the kidney of a common pathway(s) for the secretion of OCs (e.g., cimetidine, trimethoprim, metformin) sets the stage for unwanted drug-drug interactions (DDIs) (Endres et al., 2006). In addition, genetic variations of drug transporters have been linked to interindividual variations in drug efficacy, toxicity, and pharmacokinetics (Sissung et al., 2012). The clinical cost of DDIs is substantial and responsible for approximately 1% of hospital admissions (almost 5% in elderly populations) (Becker et al., 2007; U.S. Food and Drug Administration at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm), so the ability to predict potential DDIs is a commendable goal.

In the human kidney, the initial step in renal OC secretion (i.e., entry of substrate from the blood into renal proximal tubule cells) appears to be dominated by activity of the organic cation transporter homolog organic cation transporter 2 (OCT2) (Motohashi et al., 2002). Its central role in this process has made OCT2 a focal point for efforts to develop predictive models of substrate and inhibitor binding to the transport protein. Models of the interaction of ligands (including substrates and inhibitors) with OCT2 (Suhre et al., 2005; Zolk et al., 2009; Kido et al., 2011), as well as the models of ligand interaction with its hepatic homolog, OCT1 (Bednarczyk et al., 2003; Moaddel et al., 2007; Ahlin et al., 2008), typically identify charge and some measure of hydrophobicity as key determinants of ligand binding (see also Ullrich, 1997). However, the several three-dimensional...
pharmacophores that have attempted to highlight the molecular determinants of ligand-transport interaction (Bednarczyk et al., 2003; Suhre et al., 2005; Moaddel et al., 2007; Zolk et al., 2009) display similar but structurally distinct placements of hydrophobes, cationic features, and hydrogen bond donor and acceptor sites. Whereas the bases of these discrepancies could include methodological or analytical differences between these studies, we suggest another, generally unacknowledged, complicating factor, namely, the influence of substrate on OCT interaction with an inhibitor. In this regard, it is interesting that the three modeling efforts with OCT2 (and the three with OCT1) were based on profiles of inhibition of structurally distinct substrates produced by inhibitory ligands: 1-methyl-4-phenylpyridinium (MPP) (Moaddel et al., 2007; Zolk et al., 2009), TEA (Bednarczyk et al., 2003; Suhre et al., 2005), or 4-[(dimethylamino)styryl]-N-methylpyridinium iodide (Ahlin et al., 2008; Kido et al., 2011). Thus, the differences in the resulting models, noted earlier, may have reflected, at least to some degree, substrate-dependent ligand inhibition of these processes.

An influence of substrate on the profile of ligand interaction has been noted for other multidrug transporters, including P-glycoprotein (P-gp) (Ekins et al., 2002; Garrigues et al., 2002) and the organic anion transporting polypeptides (Westholm et al., 2009; Roth et al., 2011). In their extensive review of the literature, Nies et al. (2011) compiled the inhibitory profiles for a 100+ inhibitory ligands against transport activity of human OCT2 (as well as OCT1, OCT3, multixdrug and toxin extrusion transporter 1 (MATE)1 and MATE2-K). Noting the variations in IC_{50} values that were often associated with differences in probe substrate, they suggested: “The existence of various substrate and inhibitor binding sites and the complex interactions between different sites explains why largely different IC_{50} values were obtained for individual transporters when different substrates were used for transport measurements.” Although a number of observations in the literature appear to support this view (as discussed by Nies et al., 2011), so, too, are there multiple examples of similar degrees of variance in kinetic constants when different studies report IC_{50} values for inhibition of transport of the same substrate by the same test inhibitor (cf. Nies et al., 2011). Consequently, it is difficult to draw conclusions on the issue of substrate-dependent ligand interactions based on data generated by different groups. However, a recent study by Zolk et al. (2009) provided a set of observations that warrants discussion. They compared IC_{50} values for seven structurally distinct cationic drugs against OCT2-mediated transport of MPP and metformin. Lending particular credence to the idea that substrate identity may influence the interactions of inhibitory ligands with OCT2, their results showed that each test compound was a more effective (~10-fold) inhibitor of metformin than of MPP.

In the present study, we test the hypothesis that the effectiveness of cationic drugs as inhibitors of OCT2 can be significantly influenced by the substrate used in the transport assay. We confirmed the observation of Zolk et al. (2009) that cationic ligands are substantially more effective inhibitors of metformin than of MPP. This observation was then extended by comparing the inhibition of OCT2-mediated transport of the novel fluorescent cation N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]ethanaminium iodide (NBD-MTMA) that was produced by a structurally distinct battery of inhibitory ligands to the inhibition these same ligands exerted against OCT2-mediated transport of MPP and metformin. The results show that 1) the choice of OCT2 substrate significantly influences both the quantitative and the qualitative inhibitory interactions with cationic drugs; and 2) ligand interactions with OCT2 must not be restricted to competition for a common ligand binding site, consistent with a binding surface characterized by multiple, possibly overlapping interaction sites.

Materials and Methods

Reagents. Chinese hamster ovary (CHO) cells containing a single integrated flipase (Flp) recombination target site (CHO Flp-In). Flp recombinease expression plasmid, platinum high-fidelity DNA polymerase, hygromycin, Zeocin, and mammalian expression vector pcDNA5/FRT/TOPO were acquired from Invitrogen (Carlsbad, CA). Fetal bovine serum was obtained from HyClone (Logan, UT). Ham’s F-12 nutrient mixture, amitriptyline, carbamazepine, chloroquine, chloromazine, cinetidine, clonidine, diphenhydramine, disopyramide, doxepin, flecainide, imipramine, ipratropium, metformin, propafenone, propranolol, quinidine, TEA, triethylmethylenammonium, trimethoprim, and verapamil were all purchased from Sigma-Aldrich (St. Louis, MO). NBD-MTMA, 1-methyl-4-phenylepyridinium iodide (MPP), and N1-ethylacridinium were synthesized by the Synthesis Core of the Southwest Environmental Health Sciences Center/Department of Chemistry of the University of Arizona (Tucson, AZ) according to (Aavula et al., 2006). [3H]MPP (80 Ci/mmol) was synthesized by the Synthetic Chemistry Core of the Southwest Environmental Health Science Center, as was [3H]NBD-MTMA (80 Ci/mmol; see below). [14C]Metformin (107 mCi/mmol) was purchased from Moravek Biochemicals (Brea, CA).

Synthesis of [3H]NBD-MTMA. Titrated methyl iodide (31.0 mCi, 55.0 μCi, 0.38 μmol; American Radiochemicals, St. Louis, MO) in benzene (200 μl) was added to amine 1 (see Fig. 1 in Aavula et al., 2006) (1.0 mg, 3.7 μmol); the mixture was contained in a clean, conical, heavy-walled glass vial (3 ml), and the vial was sealed with a polytetrafluoroethylene-lined screw cap. The vial was kept in a secondary container (glass bottle) within a tertiary container (glass bottle) along with a piece of filter paper. The mixture was stirred for 3 weeks at room temperature. The filter paper was then checked for radioactivity, which was found to be negligible. The solution was then cooled to approximately 5°C, and a mixture of water (0.5 ml) and ethyl acetate (0.5 ml) was added. After careful mixing, the aqueous layer was removed using a gas-tight syringe. The aqueous layer was subjected to additional washing with ethyl acetate (2 × 0.5 ml). The aqueous solution was then assayed for radioactivity and was found to contain 27.3 mCi of the desired salt (138.8 μCi, 0.34 μmol, 88%). Analysis by paper chromatography showed that the compound was >90% pure.

Cell Culture and Stable Expression of OCT2. CHO cells and human embryonic kidney (HEK293) cells containing the Flp recombination target site were obtained from Invitrogen. CHO cells were grown in Ham’s F-12 Nutrient Mixture with 10% fetal bovine serum and supplemented with 100 μg/ml Zeocin. HEK293 cells were grown in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum with 100 μg/ml blasticidin. Cells that stably expressed OCT2 were prepared using methods described previously (Pelis et al., 2007). The OCT2-expressing cells were grown and maintained under hygromycin pressure (100 μg/ml) in plastic cell culture flasks at 37°C in a humidified atmosphere with 5% CO_2. Cells were passed every 3 to 4 days and seeded into 48-well plates at 137,500 cells/well and typically used 48 hours later.

Transport Studies: Radiolabeled Substrates. CHO and HEK293 cells grown to confluence in 48-well plates were rinsed twice with Waymouth buffer (WB) (135 mM NaCl, 13 mM HEPES, 2.5 mM CaCl_2·2H_2O, 1.2 mM MgCl_2, 0.8 mM MgSO_4·7H_2O, 5 mM KCl, and...
expressed OCT2 was linear for at least 90 seconds (unpublished data), so 1-minute uptakes were used for all subsequent studies of transport kinetics. To establish the kinetics of OCT2-mediated MPP transport, the rate of [$^3$H]MPP (~10–30 nM) into cells that stably expressed the transporter was measured in the presence of increasing concentrations of unlabeled MPP (Fig. 1) (there was little or no blockable transport of labeled MPP in nontransfected cells; e.g., Zhang et al., 2012). The relationship was adequately described by the Michaelis-Menten equation (eq. 1) for competitive interaction of labeled and unlabeled substrate (Malo and Berteloot, 1991):

\[ J^p = \frac{J_{\text{max}}[S^*]}{K_t + [S^*] + D_{\text{un}}[S^*]} \]  

(1)

where $J^p$ is the rate of transport of the radiolabeled substrate (in this case, [$^3$H]MPP) from a concentration of the labeled substrate equal to $[S^*]$; $J_{\text{max}}$ is the maximal rate of mediated substrate transport; $K_t$ is the Michaelis constant of the transported substrate; $[S]$ is the concentration of unlabeled substrate; and $D_{\text{un}}$ is a first-order rate constant that describes the nonsaturable component of labeled substrate accumulation (reflecting the combined influence of diffusion, non-specific binding, and incomplete rinsing of labeled substrate from the cell culture well). As determined in three separate, paired experiments, assessing the kinetics of OCT2-mediated MPP transport when stably expressed in HEK293 cells or CHO cells, there was no difference in the values of either $K_t$ (9.2 ± 0.4 versus 9.4 ± 0.3 μM). In these paired experiments, there was no difference in $J_{\text{max}}$ either (29.2 ± 5.9 versus 24.0 ± 0.6 pmol cm$^{-2}$ min$^{-1}$) (Fig. 1), although over the course of our entire study, the OCT2-expressing HEK293 line of cells tended to display slightly higher rates of transport compared with the CHO line of cells [tracer clearance of 2.8 ± 0.6 (S.D.); n = 29] versus 2.0 ± 0.8 (S.D.; n = 31) μl cm$^{-2}$ min$^{-1}$, respectively). Expressed per milligram of membrane protein, these $J_{\text{max}}$ values were (approximately) 650 pmol mg$^{-1}$ min$^{-1}$. These data suggest that kinetic values for OCT2 determined when expressed in CHO cells can be expected to be reasonably comparable to those obtained when OCT2 is expressed in HEK293 cells. Importantly, these values for the kinetics of OCT2-mediated MPP transport, obtained using our experimental and analytical methods, are also quite similar to those reported by Zolk et al. (2009); $K_t$ of 19.5 μM and $J_{\text{max}}$ of 579 pmol mg$^{-1}$ min$^{-1}$, lending further credence to the upcoming comparisons of data reported here with those reported by the Zolk group.

**Ligand Inhibition of OCT2-Mediated MPP Transport.** To expand our comparison of the influence of expression system on the kinetics of ligand interaction with OCT2, we compared the influence of an inhibitory ligand on MPP transport when OCT2 was expressed in CHO versus HEK293 cells. Figure 1B shows the kinetic profile for inhibition of OCT2-mediated MPP transport as expressed in CHO and HEK293 cells, which was produced by the structurally distinct inhibitory ligand (and OCT2 substrate) metformin (see Fig. 4), a comparison that also displays our analytical approach for such measurements. For this (and all the other) compound(s) tested, uptake of [$^3$H]MPP was inhibited by increasing concentrations of test agent according to the relationship shown in eq. 2:
Fig. 1. (A) Effect of increasing concentration of unlabeled MPP on the rate of [3H]MPP uptake into HEK293 cells or CHO cells that stably expressed OCT2. Each point is the mean (± S.E.) of 1-minute uptakes of 33 nM [3H]MPP (determined in triplicate) measured in three separate experiments with each cell line. Inset: the same data presented as total MPP uptake (% control) vs [MPP] for CHO cells. The solid line reflects linear regression (r = 0.99) of the log of the IC50 values (with S.E.) of 1-minute uptakes of 33 nM [3H]MPP (the latter value approximately equal to the IC50 value reported by Zolk et al. 2009) (Fig. 2; Table 1). Only one of the compounds, chloroquine (filled circle in Fig. 2), displayed markedly different (8-fold) IC50 values in the two studies. To examine the potential basis for this discrepancy, we compared directly the IC50 values for inhibition of OCT2-mediated MPP transport determined using our methods with those reported for the same compounds by Zolk et al. (2009). These data are presented in Fig. 2 as the log of our values versus the log of those reported by Zolk et al. (2009) (Fig. 2 Table 1). Only one of the compounds, chloroquine (filled circle in Fig. 2), displayed markedly different (8-fold) IC50 values in the two studies. To examine the potential basis for this discrepancy, we compared directly the IC50 value for chloroquine’s inhibition of 10 nM MPP (129 μM, n = 4) with that obtained in two experiments that used a substrate concentration of 10 μM MPP (the condition used in the Zolk et al., 2009 study); that value was 271 μM (± 45 μM). It is noteworthy that, presuming chloroquine is a competitive inhibitor of OCT2-mediated MPP transport (an untested assumption), the increase in substrate concentration from 10 nM to 10 μM (the latter value approximately equal to the Kt for OCT2-mediated MPP transport in our experiments; Fig. 1A) should approximately double the IC50 value (i.e., from 129 μM to approximately 260 μM), similar to our value of 271 μM but still 4-fold lower than the 1096 μM IC50 value reported by Zolk.

Additional issues arise, however, when comparing the kinetic values determined in separate studies because of the possibility that differences in the technical approach to the measurement of transport may influence the outcome. Therefore, given our intention to draw conclusions based on an “intergroup” comparison of kinetic values, we selected 10 test compounds included in the Zolk study and compared the IC50 values for inhibition of OCT2-mediated MPP transport determined using our methods with those reported for the same compounds by Zolk et al. (2009). These data are presented in Fig. 2 as the log of our values versus the log of those reported by Zolk et al. (2009) (Fig. 2 Table 1). Only one of the compounds, chloroquine (filled circle in Fig. 2), displayed markedly different (8-fold) IC50 values in the two studies. To examine the potential basis for this discrepancy, we compared directly the IC50 value for chloroquine’s inhibition of 10 nM MPP (129 μM, n = 4) with that obtained in two experiments that used a substrate concentration of 10 μM MPP (the condition used in the Zolk et al., 2009 study); that value was 271 μM (± 45 μM). It is noteworthy that, presuming chloroquine is a competitive inhibitor of OCT2-mediated MPP transport (an untested assumption), the increase in substrate concentration from 10 nM to 10 μM (the latter value approximately equal to the Kt for OCT2-mediated MPP transport in our experiments; Fig. 1A) should approximately double the IC50 value (i.e., from 129 μM to approximately 260 μM), similar to our value of 271 μM but still 4-fold lower than the 1096 μM IC50 value reported by Zolk.

Substrate-Dependent Ligand Inhibition of OCT2 303

\[
J_\text{mapp} = \frac{J_\text{max}[S^\bullet]}{IC_{50} + [I]} + D_{\text{m}}[S^\bullet]
\]  

where IC50 is the concentration of the inhibitor [I] that reduced mediated (i.e., blockable) [3H]MPP transport by 50%; Jmapp is the product of the maximum rate of S\(^\bullet\) (i.e., [3H]MPP) uptake (Jmax) and the ratio of the IC50 of the test agent and Kt for transport of S\(^\bullet\) (Groves et al., 1994). In three separate experiments using OCT2-expressing CHO cells, the IC50 for metformin inhibition of MPP transport was 545 ± 26 μM. In five separate experiments using OCT2-expressing HEK293 cells, the IC50 for metformin’s inhibition of MPP transport was 580 ± 129 μM; neither of these values was different from the IC50 value of 398 μM reported by Zolk et al. (2009). Figure 1C compares the IC50 values for the inhibition of MPP transport for three additional compounds (imipramine, clonidine, and cimetidine), as well as apparent Kt values obtained for three transported substrates (MPP, TEA, and metformin), determined using our transport protocol with OCT2-expressing CHO and HEK293 cells; the values effectively fell on the line of identity. We conclude from these observations that the transport kinetics for OCT2 determined using these different expression systems are, at least on average, reasonably comparable.

Additional issues arise, however, when comparing the kinetic values determined in separate studies because of the possibility that differences in the technical approach to the measurement of transport may influence the outcome. Therefore, given our intention to draw conclusions based on an “intergroup” comparison of kinetic values, we selected 10 test compounds included in the Zolk study and compared the IC50 values for inhibition of OCT2-mediated MPP transport determined using our methods with those reported for the same compounds by Zolk et al. (2009). These data are presented in Fig. 2 as the log of our values versus the log of those reported by Zolk et al. (2009) (Fig. 2; Table 1). Only one of the compounds, chloroquine (filled circle in Fig. 2), displayed markedly different (8-fold) IC50 values in the two studies. To examine the potential basis for this discrepancy, we compared directly the IC50 value for chloroquine’s inhibition of 10 nM MPP (129 μM, n = 4) with that obtained in two experiments that used a substrate concentration of 10 μM MPP (the condition used in the Zolk et al., 2009 study); that value was 271 μM (± 45 μM). It is noteworthy that, presuming chloroquine is a competitive inhibitor of OCT2-mediated MPP transport (an untested assumption), the increase in substrate concentration from 10 nM to 10 μM (the latter value approximately equal to the Kt for OCT2-mediated MPP transport in our experiments; Fig. 1A) should approximately double the IC50 value (i.e., from 129 μM to approximately 260 μM), similar to our value of 271 μM but still 4-fold lower than the 1096 μM IC50 value reported by Zolk.
Comparison of IC₅₀ values for the inhibition of OCT2-mediated MPP transport in the present study (column A) or in the study of Zolk et al. (2009) (column B)

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>A IC₅₀ (µM)</th>
<th>B IC₅₀ (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipramine</td>
<td>3.9 ± 0.9</td>
<td>6</td>
</tr>
<tr>
<td>Clonidine</td>
<td>6.0 ± 1.1</td>
<td>16</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>55.2 ± 4.2 (3)</td>
<td>63</td>
</tr>
<tr>
<td>Propranolol</td>
<td>71.6 ± 8.1 (2)</td>
<td>229</td>
</tr>
<tr>
<td>Verapamil</td>
<td>91.9 ± 55.6 (2, 2)</td>
<td>85</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>129 ± 22.0 (4)</td>
<td>1096</td>
</tr>
<tr>
<td>Quinidine</td>
<td>91.6 ± 27.6 (5, 2)</td>
<td>87</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>171 ± 51.0 (7, 4)</td>
<td>120</td>
</tr>
<tr>
<td>Metformin</td>
<td>566 ± 107 (3, 5)</td>
<td>398</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>775 ± 264 (4)</td>
<td>1318</td>
</tr>
</tbody>
</table>

IC₅₀ values represent the mean (± S.E.M.) of the number of separate experiments indicated in parentheses. In some cases the values include experiments with OCT2 expressed in both Chinese hamster ovary and HEK293 cells (HEK293 values indicated in italics).

The values were obtained from graphical interpolation of data presented in Fig. 3c from Zolk et al. (2009).

Kinetic Profiles of Ligand Inhibition of OCT2-Mediated Transport of MPP and Metformin. Figure 3A is a redrawing of data from the study by Zolk et al. (2009) that compared IC₅₀ values for inhibition of OCT2-mediated metformin transport with those for the inhibition of MPP transport. The observation emphasized by these researchers was the clear correlation between the IC₅₀ values for inhibition of these structurally distinct substrates produced by a common set of inhibitory ligands. Not commented on, however, was the observation that the inhibitory ligands were, on average 10.1 (±2.2) times more effective inhibitors of metformin transport than of the MPP transport. This substrate-dependent inhibitory profile has intriguing implications concerning the mechanism of ligand interaction with OCT2. Simply put, if MPP, metformin, and inhibitor compete for a common binding site, then the inhibitor should have a single IC₅₀ value (i.e., Kᵢ) for inhibition of the two substrates. It should be noted that whereas the metformin substrate concentration used in the determination of inhibitory ligand IC₅₀ values by Zolk et al. (2009) was < < than the apparent Kᵢ for OCT2-mediated metformin transport, that was not the case for MPP; as noted earlier, the MPP substrate concentration used in those experiments was 10 µM, which is sufficiently close to the apparent Kᵢ for MPP transport these authors measured (20 µM) that it is likely that at least some of the IC₅₀ values they reported modest (<50%) overestimates of the “true” Kᵢ values for any of the ligands studied that interacted competitively with MPP. However, to the extent that was the case (and we have shown that for at least some of these ligands, the interactions are noncompetitive or mixed-type rather than competitive) (Harper and Wright, 2013), the MPP IC₅₀ values still exceed by more than 7-fold those for metformin. We build on this idea in an upcoming section, but here we show that this observation by Zolk et al. is one we could reproduce. Figure 3B presents our own comparison of IC₅₀ values for the inhibition of OCT2-mediated metformin and MPP transport, including four of the same inhibitory ligands used in the study by Zolk et al. (2009) (shaded gray symbols). We also saw a strong correlation between the relative inhibition of metformin and MPP transport; but of particular relevance, and consistent with the observations of Zolk and colleagues (Zolk et al., 2009), the test inhibitory ligands were 9.2 (±0.5) times more effective inhibitors of metformin transport than of MPP transport (median value, 9.4) (P < 0.001). This observation suggests that the disparity in IC₅₀ values for the inhibition of OCT2-mediated MPP and metformin transport evident in data reported by Zolk et al. is a real phenomenon that argues for a substrate dependence for the interaction of at least these ligands with OCT2.

Ligand Inhibition of OCT2-Mediated Transport of the Fluorescent Cation NBD-MTMA. To determine whether the substrate dependence of inhibitory ligand interaction with OCT2 might be a general phenomenon (rather than restricted to MPP and metformin), we determined the profile of inhibition of OCT2-mediated transport of a structurally distinct substrate. We also took this opportunity to introduce to this type of work a novel OCT substrate with optical (i.e., fluorescent) properties that may prove useful for high-throughput applications. Some years ago, we described the synthesis of a novel fluorescent compound, [2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)aminoethyl]trimethylammonium (NBD-TMA) and its use as a substrate of basolateral OC transport into isolated, single,
nonperfused renal proximal tubules (Bednarczyk et al., 2000). We subsequently reported (Aavula et al., 2006) the synthesis of a modest structural variation of NBD-TMA that both eliminated the modest pH sensitivity of NBD-TMA and shifted the excitation and emission peaks of the resulting compound, NBD-MTMA (Fig. 4), to overlap those of the widely used fluorescent organic anion, fluorescein (490 and 540 nm, respectively). NBD-MTMA is 1) highly soluble; 2) insensitive to pH and halide concentration (Aavula et al., 2006); 3) quite fluorescent in aqueous solution (compared with fluorescein, fluorescence of NBD-MTMA in aqueous solution is approximately 10% that of an equimolar solution of fluorescein; in DMSO, NBD-MTMA fluorescence is approximately 30% that of fluorescein in aqueous solution; unpublished data); and 4) does not bind to or intercalate into cell membranes. Figure 5 shows that increasing concentrations of NBD-MTMA inhibited the OCT2-mediated transport of MPP and metformin. However, the IC50 values differed significantly: in three separate experiments comparing the inhibition by NBD-MTMA of OCT2-mediated transport, the IC50 values for MPP and metformin were 64 ± 10 μM and 8.3 ± 1.7 μM, respectively.

We next determined whether the fluorescence of NBD-MTMA is sufficient to assess whether it is a substrate, as well as an inhibitor, of OCT2. Figure 6A shows the time course of 10 μM NBD-MTMA uptake into OCT2-expressing and wild-type CHO cells. Accumulation of fluorescence by CHO-wild-type CHO cells was minimal, and uptake into CHO-OCT2 cells was linear for at least 5 minutes. Figure 6B compares the time course of OCT2-specific uptake of 1, 10, and 100 μM NBD-MTMA; at all concentrations, uptake was linear for at least 5 minutes.

The kinetic values obtained by Zolk et al. (2009) that served as a standard for the upcoming comparisons with data obtained using the fluorescent properties of NBD-MTMA differed significantly: in three separate experiments comparing the inhibition by NBD-MTMA of OCT2-mediated transport, the IC50 values for MPP and metformin were 64 ± 10 μM and 8.3 ± 1.7 μM, respectively.

Substrate-Dependent Ligand Inhibition of OCT2

![Fig. 4](image)

**Fig. 4.** Two-dimensional structures of the three OCT2 substrates used in this study: MPP, metformin, and NBD-MTMA. The Tanimoto similarities were calculated using ChemMine Web Tools (http://chemmine.ucr.edu/).

![Fig. 5](image)

**Fig. 5.** The effect of increasing NBD-MTMA concentration on uptake of [3H]MPP (●) or [14C]metformin (○) into CHO cells that stably expressed OCT2. Each point is the mean (± S.E.) of 1-minute uptakes (expressed as the percentage of uptake measured in the absence of NBD-MTMA) of 16 nM [3H]MPP or 12 μM [14C]metformin (determined in triplicate) measured in three separate experiments.
were obtained using conventional radiotracer methods. Although similar in general design, the protocols associated with optical determination of transport rates differ in several respects from protocols that use radiolabeled substrates. To that end, we synthesized \(^{3}\text{H}\)NBD-MTMA and determined the kinetics of OCT2-mediated transport in the same cells. Figure 6C shows the time course of 6 nM \(^{3}\text{H}\)NBD-MTMA into OCT2-expressing and wild-type CHO cells. As seen with the accumulation of fluorescence, wild-type CHO cells displayed no mediated uptake of the radiolabeled substrate, and OCT2-mediated uptake of \(^{3}\text{H}\)NBD-MTMA was effectively linear for 5 minutes. We then measured in the same experiments 1) the fluorescence of accumulated, radiotracer-labeled NBD-MTMA and 2) accumulated radioactivity. As shown in Fig. 6D, the experimentally determined kinetics of OCT2-mediated NBD-MTMA transport were not influenced by the means of assessing the rate of uptake [i.e., the kinetic parameters based on the uptake of fluorescence (\(K_t\) of 9.0 ± 3.0 \(\mu\)M and \(J_{\text{max}}\) of 6.8 ± 0.7 pmol cm\(^{-2}\) min\(^{-1}\)] were not different from those determined from uptake of radiolabeled substrate (\(K_t\) of 9.6 ± 3.8 \(\mu\)M and \(J_{\text{max}}\) of 5.4 ± 0.6 pmol cm\(^{-2}\) min\(^{-1}\)).

The IC\(_{50}\) values for the inhibition of OCT2-mediated NBD-MTMA transport produced by 22 inhibitory ligands are listed in Table 2. These values spanned more than three orders of magnitude, with ipratropium displaying the highest apparent affinity for OCT2 (IC\(_{50}\) of 170 nM) and metformin the lowest (1.2 mM) (Fig. 7). Figure 8A compares the IC\(_{50}\) values for the inhibition of OCT2-mediated NBD-MTMA transport with those reported by Zolk et al. (2009) for the inhibition of MPP transport. Whereas there was a significant correlation between the inhibition of transport of these two substrates (\(P < 0.0001\)), the test inhibitory ligands were generally substantially more effective inhibitors of OCT2-mediated NBD-MTMA transport than of MPP transport (median value, 4.8). A more restricted (10-compound) comparison of IC\(_{50}\) values for the inhibition of OCT2-mediated NBD-MTMA transport (Table 2) transport with those we generated against MPP transport (Table 1) showed a similar correlation: the test compounds were generally more effective (2.7-fold; \(P < 0.05\)).
IC50 values may overestimate (by approximately 2-fold) the affinities for OCT2. Indeed, the inhibitory ligands with the most effective inhibitors of NBD-MTMA transport than of MPP transport. Interestingly, the disparity between IC50 values was more evident for inhibitory ligands with relatively high apparent affinities for OCT2. The results presented here support two broad conclusions. First, the profile of inhibition of OCT2 activity is both quantitatively and qualitatively influenced by the choice of substrate used to assess transport. Specifically, OCT2-mediated metformin transport was approximately 10 times more sensitive to inhibition by a structurally diverse array of cationic drugs than was OCT2-mediated transport of MPP; transport of the structurally distinct OCT2 substrate, NBD-MTMA, displayed an intermediate sensitivity to these inhibitory ligands (i.e., it is less sensitive to inhibition than transport of metformin but more sensitive than transport of MPP). The resulting substrate dependence of drug inhibition of OCT2 transport activity, which we suggest is likely to be true for OCT1 (and other multitarget transporters), may have broad-reaching pharmacological and clinical implications with respect to practical issues of assessing the susceptibility for DDIs of new chemical entities. Second, the failure of inhibitory ligands to display the same inhibitory interaction with different substrates indicates that structurally distinct ligands may not bind at a common binding site, an observation with marked implications for the development of models of ligand interaction with OCTs.

Discussion

TABLE 2
Comparison of IC50 values for the inhibition of OCT2-mediated NBD transport (column A) or of OCT2-mediated transport of MPP (column B).

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>A^NBD IC50 μM</th>
<th>B^MPP IC50 μM</th>
<th>IC50^MPP/IC50^NBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethylacridinium</td>
<td>0.08 ± 0.01 (4)</td>
<td>15</td>
<td>88</td>
</tr>
<tr>
<td>Ipratropium</td>
<td>0.17 ± 0.05 (3)</td>
<td>13</td>
<td>8.5</td>
</tr>
<tr>
<td>Imipramine</td>
<td>1.4 ± 0.3 (5)</td>
<td>6</td>
<td>4.2</td>
</tr>
<tr>
<td>Doxepin</td>
<td>1.5 ± 0.5 (4)</td>
<td>14</td>
<td>5.7</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>2.5 ± 0.5 (4)</td>
<td>14</td>
<td>5.4</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>2.6 ± 0.4 (4)</td>
<td>14</td>
<td>5.4</td>
</tr>
<tr>
<td>MPP</td>
<td>3.0 ± 0.4 (5)</td>
<td>25</td>
<td>7.0</td>
</tr>
<tr>
<td>Propafenone</td>
<td>3.6 ± 0.5 (3)</td>
<td>16</td>
<td>3.7</td>
</tr>
<tr>
<td>Clonidine</td>
<td>4.5 ± 0.9 (5)</td>
<td>16</td>
<td>3.7</td>
</tr>
<tr>
<td>Diphenhydramine</td>
<td>5.5 ± 0.6 (3)</td>
<td>63</td>
<td>4.8</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>13.1 ± 0.7 (3)</td>
<td>63</td>
<td>4.8</td>
</tr>
<tr>
<td>Verapamil</td>
<td>21.0 ± 1.7 (3)</td>
<td>85</td>
<td>4.1</td>
</tr>
<tr>
<td>Quinidine</td>
<td>29.6 ± 5.6 (4)</td>
<td>87</td>
<td>2.9</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>39.0 ± 2.6 (6)</td>
<td>324</td>
<td>8.3</td>
</tr>
<tr>
<td>Propranolol</td>
<td>67.2 ± 7.0 (5)</td>
<td>229</td>
<td>3.4</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>70.4 ± 8.5 (5)</td>
<td>120</td>
<td>1.7</td>
</tr>
<tr>
<td>TEA</td>
<td>110 ± 14.0 (4)</td>
<td>1318</td>
<td>12</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>113 ± 14.0 (4)</td>
<td>1318</td>
<td>12</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>117 ± 9.0 (3)</td>
<td>1096</td>
<td>9.3</td>
</tr>
<tr>
<td>TEMA</td>
<td>125 ± 14.0 (3)</td>
<td>191</td>
<td>0.82</td>
</tr>
<tr>
<td>Plicainide</td>
<td>234 ± 3.0 (2)</td>
<td>397</td>
<td>0.34</td>
</tr>
<tr>
<td>Metformin</td>
<td>1180 ± 138 (4)</td>
<td>397</td>
<td>0.34</td>
</tr>
</tbody>
</table>

TEMA, triethylmethylammonium.

Numbers represent the mean (± S.E.) of the number of separate experiments, performed OCT2-expressing CHO cells, indicated in parentheses.

Values were obtained from Table 1 in Zolk et al. (2009).

as approximating true \( K_i \) values (Segel, 1975). However, in the experiments that generated the data in Table 2, the concentration of NBD-MTMA substrate was 10 μM, essentially equal to its \( K_i \) value (Fig. 6D). Consequently, in the event that the interaction of NBD-MTMA with an inhibitory ligand was competitive, the resulting IC50 value is likely to overestimate actual \( K_i \) value by approximately 2-fold (non-competitive and mixed-type interactions would be less affected by the comparatively high concentration of substrate) (Segel, 1975). Thus, the difference in the inhibitory efficacy of the test inhibitory ligands when blocking NBD-MTMA versus MPP transport is likely to be even greater than indicated in Fig. 8A, which shows the ratio of (measured) IC50 values for the test inhibitory ligands against the two substrates and emphasizes that the degree of deviation from identical IC50 values was not a constant; it varied from a 3-fold difference toward more effective inhibition of MPP (metformin) to an 88-fold difference toward more effective inhibition of NBD-MTMA (ipratropium). Figure 9 shows the relationship between the (measured) IC50 values for the inhibition of OCT2-mediated NBD-MTMA transport and the IC50 values for the inhibition of OCT2-mediated metformin transport (open symbols indicate values measured by us; solid symbols show the values reported by Zolk et al., 2009). Again, there was a significant correlation between the inhibition of transport of these two substrates (\( P < 0.0001 \)) (i.e., the most effective inhibitors of metformin transport were generally the most effective inhibitors of NBD-MTMA transport); but for these two substrates, the inhibitory ligands were generally more effective inhibitors of metformin transport than of NBD-MTMA (median value of 3.6 for the ratio of IC50\[^{NBD-MTMA}\]/IC50\[^{metformin}\] (Table 3).

Fig. 7. The effect of increasing inhibitor concentration on the rate of NBD-MTMA uptake into CHO cells that stably expressed OCT2. Each point is the mean (± S.E.) of five minute uptakes (expressed as the percentage of uptake measured in the absence of inhibitor) of 10 nM [3H]MPP (determined in triplicate) measured in three to four separate experiments.
IC50 values for inhibition of MPP than for either metformin or showing that inhibitory ligands routinely displayed higher (Segel, 1975). Consequently, the evidence presented here have same for a common binding site is that an inhibitory ligand will interaction of transported substrates, need not be competi-

conclusion that ligand interaction with OCT2, including the mixed-type as well as competitive interactions (Harper and Wright, 2013). The data presented here similarly support the hypothesis that OCTs have multiple, spatially distinct binding sites within a large polyspecific substrate binding pocket. In light of the evidence that profiles of ligand inhibition of OCT-meditated transport are influenced, both qualitatively and quantitatively, by the choice of substrate (e.g., Fig. 8), the “universality” of pharmacophores based on inhibition of a single substrate must be called into question. It may also explain the differences in the principal features identified in studies using different probe substrates. For example, we previously described a pharmacophore, based on OCT2-mediated TEA transport that was characterized by 1)

Fig. 8. (A) Relationship between IC50 values for inhibition of OCT2-mediated transport of NBD-MTMA (x-axis; Table 1 in the present report) and MPP (y-axis; as reported in Table 1 of Zolk et al., 2009). The dashed line indicates the line of identity (equal IC50 values; light curved lines indicate 95% confidence interval). The heavy solid line reflects linear regression (r = 0.84) of the log of the IC50 values. The points represent mean values (± S.E.) determined in separate experiments (two to six in the present study, Table 1; reported as three in Zolk et al., 2009). (B) Ratio of IC50 value for inhibition of OCT2-mediated MPP transport to the value for inhibition of NBD-MTMA transport. The dashed line indicates the median value (5.1) for this ratio.

frequently assumed, either explicitly (e.g., Tahara et al., 2005; Amphoux et al., 2006) or implicitly (e.g., Muller et al., 2005), that the inhibition of OCT-mediated transport produced by small cations is competitive. However, we recently reported that such assumptions are unwarranted; ligand inhibition of OCT2-mediated MPP transport involves noncompetitive and mixed-type as well as competitive interactions (Harper and Wright, 2013). The data presented here similarly support the conclusion that ligand interaction with OCT2, including the interaction of transported substrates, need not be competitive. One of the principal predictions of mutual competition for a common binding site is that an inhibitory ligand will have same $K_i$ (IC50) value for inhibition of different substrates (Segel, 1975). Consequently, the evidence presented here showing that inhibitory ligands routinely displayed higher IC50 values for inhibition of MPP than for either metformin or NBD-MTMA argues that these compounds (inhibitors and substrates) cannot interact with a common (or mutually exclusive set of) binding site(s). In retrospect, this is not a surprising observation. The hallmark “multisubstrate specificity” (Ullrich, 1997) of renal OC transporters makes it difficult to reconcile the structural diversity of molecules like MPP and NBD-MTMA (Fig. 4) and the observation that the apparent affinity of OCT2 for both is quantitatively similar ($K_i$ of 9 μM; Figs. 1 and 6) with the idea of their binding to a common site. Furthermore, there is growing acceptance that ligand binding with other multidrug binding proteins involves interaction with spatially distinct sites within a larger binding surface. The kinetics of ligand inhibition of P-gp-mediated transport shows a clear substrate dependency (e.g., Ekins et al., 2002; Garrigues et al., 2002), as does the interaction of selected inhibitors with OATP-mediated transport Westholm et al., 2009; Roth et al., 2011). Moreover, X-ray crystal structures of P-gp (Aller et al., 2009) and the multidrug-binding transcription regulator QacR (Schumacher and Brennan, 2003) reveal the presence of multisite binding pockets. With respect to the OCTs, a number of studies have suggested that inhibitors of OCT transport display allosteric interactions at multiple sites (e.g., Volk et al., 2003, 2009; Popp et al., 2005; Lee et al., 2009; Minuesa et al., 2009; Egenberger et al., 2012). Furthermore, the results of site-directed studies of OCT function consistently suggest that substrates must interact with spatially distinct sites within the large hydrophobic translocation pathway suspected to exist with OCT1 (Popp et al., 2005) and OCT2 (Zhang et al., 2005; Pelis et al., 2006). Mutation of a single residue in rOCT1 (D475E) exerts a profound effect on the affinity of the transporter for TEA and choline without having an effect on the kinetics of MPP transport (Gorboulev et al., 1999). Similarly, changing residue 447 in OCT2 (which imparts the marked difference in selectivity of OCT1 versus OCT2 for cimetidine) from glutamate to leucine effectively eliminates the transport of TEA and cimetidine but has no effect on MPP transport (Zhang et al., 2005), and mutation of C474 (adjacent to the aforementioned D475) markedly influences the apparent affinity of OCT2 for MPP but not TEA (Pelis et al., 2012). Taken with the observations reported here, the results of these studies support the hypothesis that OCTs have multiple, spatially distinct binding sites within a large polyspecific substrate binding pocket.

Insight into structural features that may influence spatially distinct ligand interaction with MATE1 may be found by comparing the structures of the three probe substrates. Of the three, metformin stands out in the absence of an aromatic feature (Fig. 4). With this in mind, it is interesting that the tested inhibitory ligands were generally more effective inhibitors of metformin transport than of MPP and NBD-MTMA transport, both of which possess multiple ring structures. The absence of an aromatic feature in metformin, and the generally stronger effectiveness of the tested ligands as inhibitors of MATE1-mediated metformin transport, suggests the presence of an alternative binding site that is not shared by MPP or NBD-MTMA.

In light of the evidence that profiles of ligand inhibition of OCT-mediated transport are influenced, both qualitatively and quantitatively, by the choice of substrate (e.g., Fig. 8), the “universality” of pharmacophores based on inhibition of a single substrate must be called into question. It may also explain the differences in the principal features identified in studies using different probe substrates. For example, we previously described a pharmacophore, based on OCT2-mediated TEA transport that was characterized by 1)
In addition to the influence that substrate-dependent inhibition of OCT2 has on understanding the molecular basis of drug interaction with this transporter, it also has a marked impact on the use of defined protocols ("decision trees") designed to identify potential DDIs with OCTs, as well as other multidrug transporters, the results of which influence key decisions on the clinical and commercial future of these compounds (Giacomini et al., 2010; Lepist and Ray, 2012). For example, the current recommended guidance for initiating a clinical study of a drug’s potential for DDI with OCT1 or OCT2 is a value >0.1 for the ratio of unbound $C_{\text{max}}$ to the drug’s IC$_{50}$ for the inhibition of the transport of MPP, the prototypic OCT substrate (Giacomini et al., 2010; see U.S. Food and Drug Administration at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Drug-InteractionsLabeling/ucm110632.htm). We suggest that interactions, a tricyclic antidepressant, has an unbound $C_{\text{max}}$ of 70 nM (Thummel and Shen, 2001), and an IC$_{50}$ of 7 µM against OCT2-mediated MPP transport (Zolk et al., 2009), resulting in a $C_{\text{max}}$/IC$_{50}$ ratio of 0.01, well below the guidance limit. However, imipramine’s IC$_{50}$ against OCT2-mediated metformin transport (determined in the same study; Zolk et al., 2009) is 0.4 µM, resulting in a ratio of 0.18, which would argue for a clinical DDI study (Giacomini et al., 2010; see U.S. Food and Drug Administration at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Drug-InteractionsLabeling/ucm110632.htm). We suggest that the decision-making process be more fully informed of a substrate-dependence for inhibitor interaction with OCTs that appears to be the rule rather than the exception. In summary, structurally diverse cationic drugs were generally approximately 10 times more effective inhibitors of OCT2-mediated metformin transport than of MPP transport. A substrate-dependent inhibition profile was also seen for transport of the novel fluorescent cation NBD-MTMA; test drugs were generally less effective inhibitors of NBD-MTMA than metformin but more effective than MPP. These results suggest that substrate-dependent inhibitory ligand interaction is a common characteristic for OCT2. The results also argue for the presence within the translocation pathway of this multidrug transporter of a structurally complex binding surface than can accommodate ligand interactions with a positive charge feature and 2) a single hydrogen-bond acceptor feature (Suhre, et al., 2005), whereas the model described by Zolk et al. (2009), which was based on OCT2-mediated MPP transport, was characterized by 1) an ion interaction site and 2) a hydrophobic (aromatic ring) site. As noted earlier, these differences may well have been influenced by the composition of the respective training sets or the analytical methods used for pharmacophore generation (Catalyst v 4.9 versus LigandScout v 1.03; Accelrys, San Diego, CA, and Inte:Ligand, Vienna, Austria, respectively). However, interaction of MPP and TEA with OCT2 is mixed type rather than competitive (Harper and Wright, 2013), consistent with their interaction, both with each other and with other inhibitory ligands, at spatially distinct sites. We suggest that adequate description of ligand binding to OCT2 will require identification of a suitable cohort of structurally distinct probe substrates, as well as a structurally rich set of training inhibitors, to explore adequately the chemical space available for substrate or inhibitor interaction.

![Graph](https://via.placeholder.com/150)

**Fig. 9.** Relationship between IC$_{50}$ values for inhibition of OCT2-mediated transport of NBD-MTMA (x-axis; Table 2 in the present report) and metformin (y-axis; open symbols indicate values measured by us; solid symbols show the values reported by Zolk et al., 2009) (refer to Table 3). The dashed line indicates the line of identity (equal IC$_{50}$ values; light symbols show the values reported by Zolk et al., 2009) (refer to Table 3). The heavy solid line reflects linear regression ($r = 0.89$) of the log of the IC$_{50}$ values.

### TABLE 3

Comparison of IC$_{50}$ values for the inhibition of OCT2-mediated NBD-MTMA transport (column A) or of OCT2-mediated transport of metformin (Met) determined in the present study (column B) or in the study by Zolk et al. (2009) (column C)

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>A$^{+}$NBD-MTMA IC$_{50}$ (µM)</th>
<th>B$^{+}$Met IC$_{50}$ (µM)</th>
<th>C$^{+}$Met IC$_{50}$ (µM)</th>
<th>$^{+}$IC$<em>{50}$/IC$</em>{50}$ NBD (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipramine</td>
<td>1.4 ± 0.3 (5)</td>
<td>0.77 ± 0.29 (3)</td>
<td>0.4</td>
<td>0.55 (0.3)</td>
</tr>
<tr>
<td>Clonidine</td>
<td>4.5 ± 0.9 (5)</td>
<td>0.68 ± 0.22 (4)</td>
<td>1.5</td>
<td>0.15 (0.3)</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>13.1 ± 0.7 (3)</td>
<td>—</td>
<td>15</td>
<td>(1)</td>
</tr>
<tr>
<td>Verapamil</td>
<td>21.0 ± 1.7 (3)</td>
<td>20.0 ± 7.6 (2)</td>
<td>5</td>
<td>0.95 (0.2)</td>
</tr>
<tr>
<td>Quinidine</td>
<td>29.6 ± 5.6 (4)</td>
<td>6.4 ± 0.9 (3)</td>
<td>8</td>
<td>0.22 (0.3)</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>70.4 ± 8.5 (5)</td>
<td>25.4 ± 11.3 (4)</td>
<td>—</td>
<td>0.36</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>117 ± 9.0 (3)</td>
<td>9.6 ± 1.2 (2)</td>
<td>—</td>
<td>0.08</td>
</tr>
<tr>
<td>Flecainide</td>
<td>234 ± 3.0 (2)</td>
<td>—</td>
<td>61</td>
<td>(0.3)</td>
</tr>
</tbody>
</table>

---

*Values not obtained.

+Numbers represent the mean ($\pm$ S.E.) of the number (indicated in parentheses) of separate experiments performed OCT2-expressing CHO cells.

$^{+}$Values were obtained from Fig. 6C in Zolk et al. (2009).

$^{+}$Values in italics represent the ratio of IC$_{50}$ for inhibition of metformin transport measured by Zolk et al. (2009) versus the IC$_{50}$ for inhibition of NBD-MTMA transport measured in the present report, whereas nonitalicized values stem from the present report.
spatially distinct sites. Development of predictive models of drug interaction with OCT2 should acknowledge the need to consider interaction profiles with structurally distinct substrate.

Consideration tree protocols for assessing the potential for DDIs between new and existing drugs must acknowledge that a weak interaction between a test compound and one probe substrate may mask a more potent interaction with others.

Acknowledgments

The authors thank Dr. William Dantzler for useful discussions.

Authorship Contributions

Participated in research design: Belzer, Jagadish, Mash, Wright.

Conducted experiments: Belzer, Morales, Jagadish.

Contributed new reagents or analytic tools: Belzer, Jagadish.

Performed data analysis: Belzer, Morales, Wright.

Wrote or contributed to writing of the manuscript: Belzer, Mash, Wright.

References


Address correspondence to: Stephen H. Wright, Department of Physiology, University of Arizona, Tucson, AZ 85724. E-mail: shwright@u.arizona.edu